Lung

Most recent

Other

CamBMT1: a proof-of-principle phase Ib/randomized phase II study of afatinib penetration into brain metastases for patients undergoing neurosurgical resection, both with and without prior low-dose, targeted radiotherapy

Baird RD, et al. ESMO 2016:1318 Background Brain metastases occur in 20–40% of all patients with cancer, and 30–50% of patients with locally advanced non-small cell lung cancer will relapse in the central nervous system. Failure of drugs to cross the blood-brain...

Twitter feed

Video: Dr. Mark Vincent Discusses Outcomes in Pancreatic Adenocarcinoma Patients with Genetic Alterations in DNA Da… https://t.co/35E7MSeX3V
h J R
RT @medoncdoc: CO26. first evidence of survival benefit in MSS patients using immunotherapy. 6.6 mo vs 4.1 mo.#GI19 @CDNCancerTrials great…
h J R
RT @tehfem: Adjuvant HIPEC in CRC at high risk for peritoneal mets No benefit #GI19 https://t.co/tYIw9B3eme
h J R
RT @GillSharlene: How long to optimally wait for resection after neoadjuvant therapy for early stage rectal cancer? Looks like the answer…
h J R
Video: Dr. Winson Cheung on Prognostic Factors Associated with Long-Term Survival in Chemotherapy-Treated Advanced… https://t.co/yBP1srRQkb
h J R